ArticleMedical oncology (Northwood, London, England)2014
Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Identifying a Risk Signature of Methylation-Driven Genes as a Predictor of Survival Outcome for Colon Cancer Patients.Applied biochemistry and biotechnology · 2024Article
- STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma.Redox biology · 2023Article
- Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review.Advanced pharmaceutical bulletin · 2023Review
- Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.Journal of experimental & clinical cancer research : CR · 2022Review
- The significance of Stanniocalcin 2 in malignancies and mechanisms.Bioengineered · 2021Review
- Effect of STC2 gene silencing on colorectal cancer cells.Molecular medicine reports · 2019Article
- High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.Clinical and experimental medicine · 2017Article
- mRNA expression of nuclear factor of activated T-cells, cytoplasmic 2 (NFATc2) and peroxisome proliferator-activated receptor gamma (PPARG) transcription factors in colorectal carcinoma.Bosnian journal of basic medical sciences · 2017Article
- Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stanniocalcin 2 (STC2) is a novel member of the Stanniocalcin family, the function of which remains unclear. Its expression is clinically significant in several cancers. The aim of this study was to evaluate the clinical value of measuring expression levels of STC2 in colorectal cancer (CRC) patients. A total of 47 tumor and matched tumor-free margin samples were obtained during surgery. The STC2 mRNA expression level in tumor and marginal tissue was examined by real-time quantitative PCR. STC2 mRNA expression levels were higher in tumor tissues than the control. (r=0.36, p≤0.02). mRNA expression level of STC2 was significantly associated with tumor size (p≤0.05) and histologic grade (p≤0.05). Our study demonstrated that STC2 was significantly expressed in CRC patients, relative to the control. STC2 can therefore be used as a biomarker to differentiate between tumor borders and margins. Analysis of STC2 gene expression during surgery could be useful in reducing surgical error in tumor removal and increasing overall success of surgery with improved tumor clearance. However, in some cases such as where the tumor is end-stage, the expression of such a biomarker may not be clinically beneficial to record. The consideration of marginal samples as a control group can help reduce the effect of confounding factors such as racial and individual differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.